Docking and antibacterial activity of novel nontoxic 5-arylidenepyrimidine-triones as inhibitors of NDM-1 and MetAP-1

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. World Health Organisation. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization, Geneva, Switzerland (2017). https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/
  Google Scholar
• 2. Bebrone C. Metallo-β-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily. Biochem. Pharmacol. 74(12), 1686–1701 (2007). •• Describes the classification and structure of metallo-β-lactamases.
  Medline CASGoogle Scholar
• 3. Lima LM, da Silva BNM, Barbosa G, Barreiro EJ. β-lactam antibiotics: an overview from a medicinal chemistry perspective. Eur. J. Med. Chem. 208, 112829 (2020).
  Medline CASGoogle Scholar
• 4. Yong D, Toleman MA, Giske CG et al. Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents. Chemother. 53(12), 5046–5054 (2009).
  Medline CASGoogle Scholar
• 5. Avolio M, Vignaroli C, Crapis M, Camporese A. Co-production of NDM-1 and OXA-232 by ST16 Klebsiella pneumoniae, Italy, 2016. Fut. Microbiol. 12(13), 1119–1122 (2017).
  Medline CASGoogle Scholar
• 6. Espinal P, Nucleo E, Caltagirone M et al. Genomics of Klebsiella pneumoniae ST16 producing NDM-1, CTX-M-15, and OXA-232. Clin. Microbiol. Infect. 25, 385.e1–385.e5 (2019).
  CASGoogle Scholar
• 7. Gona F, Bongiorno D, Aprile A et al. Emergence of two novel sequence types (3366 and 3367) NDM-1- and OXA-48-co-producing K. pneumoniae in Italy. Eur. J. Clin. Microbiol. Infect. Dis. 38(9), 1687–1691 (2019).
  Medline CASGoogle Scholar
• 8. Sun Z, Hu L, Sankaran B et al. Differential active site requirements for NDM-1 β-lactamase hydrolysis of carbapenem versus penicillin and cephalosporin antibiotics. Nat. Commun. 9(1), 1–14 (2018).
  MedlineGoogle Scholar
• 9. Guo Y, Wang J, Niu G et al. A structural view of the antibiotic degradation enzyme NDM-1 from a superbug. Protein. Cell. 2(5), 384–394 (2011).
  Medline CASGoogle Scholar
• 10. Khan AU, Maryam L, Zarrilli R. Structure, genetics and worldwide spread of New Delhi metallo-β-lactamase (NDM): a threat to public health. BMC Microbiol. 17(1), 101 (2017).
  MedlineGoogle Scholar
• 11. Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin. Microbiol. Infect. 20(9), 821–830 (2014).
  Medline CASGoogle Scholar
• 12. Reddy N, Shungube M, Arvidsson PI et al. A 2018–2019 patent review of metallo-beta-lactamase inhibitors. Expert. Opin. Ther. Pat. 30(7), 541–555 (2020).
  Medline CASGoogle Scholar
• 13. Behzadi P, García-Perdomo HA, Karpiński TM, Issakhanian L. Metallo-ß-lactamases: a review. Mol. Biol. Rep. 47, 6281–6294 (2020).
  Medline CASGoogle Scholar
• 14. Kang PW, Su JP, Sun LY et al. 3-Bromopyruvate as a potent covalently reversible inhibitor of New Delhi metallo-β-lactamase-1 (NDM-1). Eur. J. Pharm. Sci. 142, 105161 (2019).
  MedlineGoogle Scholar
• 15. Chen AY, Thomas C, Thomas PW et al. Iminodiacetic acid as a novel metal-binding pharmacophore for New Delhi metallo-β-lactamase inhibitor development. ChemMedChem. 15(14), 1272–1282 (2020).
  Medline CASGoogle Scholar
• 16. Helgren TR, Wangtrakuldee P, Staker BL, Hagen TJ. Advances in bacterial methionine aminopeptidase inhibition. Curr. Top. Med. Chem. 16(4), 397–414 (2016). ••Describes the structure and inhibitors of MetAP-1.
  Medline CASGoogle Scholar
• 17. Frottin F, Martinez A, Peynot P et al. The proteomics of N-terminal methionine cleavage. T. Mol. Cell. Proteomics. 5(12), 2336–2349 (2006).
  Medline CASGoogle Scholar
• 18. Swierczek K, Copik AC, Swierczek SI, Holz RC. Molecular discrimination of type-I over type-II methionyl aminopeptidases. Biochemistry. 44(36), 12049–12056 (2005).
  Medline CASGoogle Scholar
• 19. Willow M, Johnston GAR. Pharmacology of barbiturates: electrophysiological and neurochemical studies. Int. Rev. Neurobiol. 24, 15–49 (1983).
  Medline CASGoogle Scholar
• 20. Jeong YC, Moloney MG. Antibacterial barbituric acid analogues inspired from natural 3-acyltetramic acids; synthesis, tautomerism and structure and physicochemical property-antibacterial activity relationships. Molecules. 20(3), 3582–3627 (2015).
  Medline CASGoogle Scholar
• 21. Figueiredo J, Serrano JL, Soares M et al. 5-Hydrazinylethylidenepyrimidines effective against multidrug-resistant Acinetobacter baumannii: synthesis and in vitro biological evaluation of antibacterial, radical scavenging and cytotoxic activities. Eur. J. Pharm. Sci. 137, 104964 (2019).
  Medline CASGoogle Scholar
• 22. Penthala NR, Ketkar A, Sekhar KR et al. 1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: anti-cancer agents that target nucleophosmin 1 (NPM1). Bioorg. Med. Chem. 23(22), 7226–7233 (2015).
  Medline CASGoogle Scholar
• 23. Xu C, Wyman AR, Alaamery MA et al. Anti-inflammatory effects of novel barbituric acid derivatives in T lymphocytes. Inter. Immunopharmacology 38, 223–232 (2016).
  Medline CASGoogle Scholar
• 24. Laxmi SV, Reddy YT, Kuarm BS et al. Synthesis and evaluation of chromenyl barbiturates and thiobarbiturates as potential antitubercular agents. Bioorg. Med. Chem. Lett. 21(14), 4329–4331 (2011).
  MedlineGoogle Scholar
• 25. Sokmen BB, Ugras S, Sarikaya HY et al. Antibacterial, antiurease, and antioxidant activities of some arylidene barbiturates. Appl. Biochem. Biotechnol. 171(8), 2030–2039 (2013).
  Medline CASGoogle Scholar
• 26. Haldar MK, Scott MD, Sule N et al. Synthesis of barbiturate-based methionine aminopeptidase-1 inhibitors. Bioorg. Med. Chem. Lett. 18(7), 2373–2376 (2008).
  Medline CASGoogle Scholar
• 27. Klingler FM, Wichelhaus TA, Frank D et al. Approved drugs containing thiols as inhibitors of metallo-β-lactamases: strategy to combat multidrug-resistant bacteria. J. Med. Chem. 58(8), 3626–3630 (2015). • Describes the different thiol inhibitors of metallo-β-lactamases.
  Medline CASGoogle Scholar
• 28. Douangamath A, Dale GE, D'Arcy A et al. Crystal structures of Staphylococcus aureus methionine aminopeptidase complexed with keto heterocycle and aminoketone inhibitors reveal the formation of a tetrahedral intermediate. J. Med. Chem. 47(6), 1325–1328 (2004).
  Medline CASGoogle Scholar
• 29. Hsu KC, Chen YF, Lin SR, Yang JM. iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC Bioinformatics. 12(1), S33 (2011).
  MedlineGoogle Scholar
• 30. O'Boyle NM, Banck M, James CA et al. Open babel: an open chemical toolbox. J. Cheminform. 3(1), 33 (2011).
  MedlineGoogle Scholar
• 31. Casewit CJ, Colwell KS, Rappe AK. Application of a universal force field to organic molecules. J. Am. Chem. Soc. 114(25), 10035–10046 (1992).
  CASGoogle Scholar
• 32. Cole JC, Nissink JWM, Taylor R. Protein–ligand docking and virtual screening with GOLD. In: Virtual Screening in Drug Discovery. Taylor & Francis CRC Press, FL, USA (2005).
  Google Scholar
• 33. Harpole TJ, Delemotte L. Conformational landscapes of membrane proteins delineated by enhanced sampling molecular dynamics simulations. Biochim. Biophys. Acta. 1860(4), 909–926 (2018).
  CASGoogle Scholar
• 34. Devillers J, Steiman R, Seigle-Murandi F. The usefulness of the agar-well diffusion method for assessing chemical toxicity to bacteria and fungi. Chemosphere. 19(10–11), 1693–1700 (1989).
  CASGoogle Scholar
• 35. Pires DE, Blundell TL, Ascher DB. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 58(9), 4066–4072 (2015).
  Medline CASGoogle Scholar
• 36. King D, Strynadka N. Crystal structure of New Delhi metallo-β-lactamase reveals molecular basis for antibiotic resistance. Protein. Sci. 20(9), 1484–91 (2011).
  Medline CASGoogle Scholar
• 37. Thomas PW, Zheng M, Wu S et al. Characterization of purified New Delhi metallo-beta-lactamase-1. Biochemistry. 50(46), 10102–10113 (2011).
  Medline CASGoogle Scholar
• 38. Moali C, Anne C, Lamotte-Brasseur J et al. Analysis of the importance of the metallo-β-lactamase active site loop in substrate binding and catalysis. Chem. Biol. 10(4), 319–329 (2003).
  Medline CASGoogle Scholar
• 39. Meini MR, Llarrull L, Vila A. Evolution of metallo-β-lactamases: trends revealed by natural diversity and in vitro evolution. Antibiotics. 3(3), 285–316 (2014).
  Google Scholar
• 40. Sharma S, Sharma S, Singh PP, Khan IA. Potential inhibitors against NDM-1 Type metallo-β-lactamases: an overview. Microb. Drug Resist. 26(12), 1568–1588 (2020).
  Medline CASGoogle Scholar
• 41. Cheng Z, Thomas PW, Ju L et al. Evolution of New Delhi metallo-beta-lactamase (NDM) in the clinic: effects of NDM mutations on stability, zinc affinity, and mono-zinc activity. J. Biol. Chem. 293(32), 12606–12618 (2018).
  Medline CASGoogle Scholar
• 42. Mojica MF, Bonomo RA, Fast W. B1-Metallo-β-Lactamases: where do we stand? Curr. Drugs. Targets. 17(9), 1029–1050 (2016).
  Medline CASGoogle Scholar
• 43. Linciano P, Cendron L, Gianquinto E et al. Ten years with New Delhi metallo-β-lactamase-1 (NDM-1): from structural insights to inhibitor design. ACS Infect. Dis. 5(1), 9–34 (2018). •• Describes the structure and classification of different classes inhibitors of NDM-1.
  MedlineGoogle Scholar
• 44. Lowther WT, Orville AM, Madden DT et al. Escherichia coli methionine aminopeptidase: implications of crystallographic analyses of the native, mutant, and inhibited enzymes for the mechanism of catalysis. Biochemistry. 38(24), 7678–7688 (1999).
  Medline CASGoogle Scholar
• 45. Evdokimov AG, Pokross M, Walter RL et al. Serendipitous discovery of novel bacterial methionine aminopeptidase inhibitors. Proteins Struct. Funct. Bioinf. 66(3), 538–546 (2007).
  Medline CASGoogle Scholar
• 46. Kromann H, Larsen M, Boesen T et al. Synthesis of prenylated benzaldehydes and their use in the synthesis of analogues of licochalcone A. Eur. J. Med. Chem. 39(11), 993–1000 (2004).
  Medline CASGoogle Scholar
• 47. Rampersad SN. Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors. 12, 12347–12360 (2012).
  Medline CASGoogle Scholar
• 48. Tawakoli PN, Al-Ahmad A, Hoth-Hannig W et al. Comparison of different live/dead stainings for detection and quantification of adherent microorganisms in the initial oral biofilm. Clin. Oral. Investig. 17(3), 841–850 (2013).
  Medline CASGoogle Scholar
• 49. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 44(1), 235–249 (2000).
  Medline CASGoogle Scholar
• 50. Veber DF, Johnson SR, Cheng HY et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45(12), 2615–2623 (2002).
  Medline CASGoogle Scholar
• 51. Bocci G, Carosati E, Vayer P et al. ADME-Space: a new tool for medicinal chemists to explore ADME properties. Sci. Rep. 7(1), 6359 (2017).
  MedlineGoogle Scholar
• 52. Prachayasittikul V, Prachayasittikul V. P-glycoprotein transporter in drug development. EXCLI J. 15, 113–118 (2016).
  MedlineGoogle Scholar
• 53. Benigni R, Bossa C. Data-based review of QSARs for predicting genotoxicity: the state of the art. Mutagenesis. 34(1), 17–23 (2018).
  Google Scholar